AmbioPharm Appoints Thomas P. Wilson as Chief Commercial Officer  

North Augusta, SC, July 29, 2025– AmbioPharm, a leading global peptide CDMO (Contract Development and Manufacturing Organization), is pleased to announce the appointment of Thomas P. Wilson as Chief Commercial Officer (CCO). Mr. Wilson brings more than 30 years of experience in commercial strategy and execution as well as pharmaceutical operations, with a strong track record of driving growth and building global partnerships.   

At AmbioPharm, he will oversee global business development, account management, program management and shape the company’s go-to-market approach, with a focus on enhancing customer relationships and aligning cross-functional teams to support long-term success for our customer-partners as well as AmbioPharm. 

Prior to joining AmbioPharm, Mr. Wilson was Vice President, Contract Manufacturing Business Lead at Pfizer CentreOne, where he led the CDMO business to double-digit growth and played a key role in building billion-dollar strategic partnerships.  

Mr. Wilson holds a Master of Science in Administration and Management from St. Michael’s College and a Bachelor of Science in Physics from St. Joseph’s University. He also served as a Captain in the United States Air Force before beginning his career in the pharmaceutical industry.  

“We are thrilled to welcome Tom to the AmbioPharm leadership team. Tom’s deep knowledge of the CDMO landscape and proven ability to lead global teams makes him the right person to help take AmbioPharm to the next level,” said Brian Gregg, CEO of AmbioPharm. 

“I’m excited to join a company with such strong scientific capabilities and a clear focus on quality and customer service. I look forward to building strong, collaborative relationships with our partners and helping them bring therapies to patients,” said Wilson. 

About AmbioPharm 

AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.